相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Alicja Puszkiel et al.
CLINICAL PHARMACOKINETICS (2019)
Long-Acting Somatostatin Analog Therapy Differentially Alters 68Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions
Narjess Ayati et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA
Murat Fani Bozkurt et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Bryan Oronsky et al.
NEOPLASIA (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
Twins in spirit part II: DOTATATE and high-affinity DOTATATE-the clinical experience
Claudia Brogsitter et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature
Camilla Bardram Johnbeck et al.
FUTURE ONCOLOGY (2014)
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Martyn E. Caplin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis
Hakan Geijer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Does PRRT with standard activities of Lu-177-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors
Amir Sabet et al.
EJNMMI RESEARCH (2013)
Current knowledge on diagnosis and staging of neuroendocrine tumors
Kjell Oberg et al.
CANCER AND METASTASIS REVIEWS (2011)
Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors
Alexander R. Haug et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE
Irene Virgolini et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2-clinical implications
Mehtap Cakir et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
In vivo binding of [Ga-68]-DOTATOC to somatostatin receptors in neuroendocrine tumours - impact of peptide mass
Irina Velikyan et al.
NUCLEAR MEDICINE AND BIOLOGY (2010)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles
B Astruc et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
分享论文
